Oncocyte(OCX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch NASHVILLE, TENN., August 11, 2025 — Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to delivering a regulated kitted transplant monitoring assay to the market – and we are pleased to report a series of recent and timely accomplishments that we believe amoun ...